We serve Chemical Name:4,5-Dichlorocatechol CAS:3428-24-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4,5-Dichlorocatechol
CAS.NO:3428-24-8
Synonyms:Pyrocatechol,4,5-dichloro;4,5-DICHLOROCATECHOL;4,5-dichloroguaiacol;1,2-Benzenediol,4,5-dichloro;1,2-Benzenediol, 4,5-dichloro-;4,5-Dichloropyrocatechol;4,5-Dichloro-1,2-benzenediol;EINECS 222-331-1;MFCD00463757;4,5-dichlorobenzene-1,2-diol
Molecular Formula:C6H4Cl2O2
Molecular Weight:179.001
HS Code:2908199090
Physical and Chemical Properties:
Melting point:110-115ºC(lit.)
Boiling point:302.2±37.0 °C at 760 mmHg
Density:1.6±0.1 g/cm3
Index of Refraction:1.642
PSA:40.46000
Exact Mass:177.958832
LogP:3.29
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3077 9 / PGIII
Packing Group:
Contact us for information like Pyrocatechol,4,5-dichloro chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4,5-dichlorobenzene-1,2-diol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyrocatechol,4,5-dichloro Use and application,4,5-Dichloro-1,2-benzenediol technical grade,usp/ep/jp grade.
Related News: Only four out of the eight studies showed a reduction in ‘off’ time, and the effect did not increase with an increased dose of Nouryant.” (1S)-4-chloro-1-butanol-1-d mesylate manufacturers After a four-year battle over a cancer drug patent, Novartis has been ordered by a California judge to pay a Daiichi Sankyo subsidiary $177.8 million. 1H-Pyrazole-4-carbonitrile, 3-nitro-1-(2-propynyl)- suppliers One way of leveraging the many benefits of biocatalysis is to partner with an API CDMO offering comprehensive expertise and experience in developing and implementing such technology in GMP commercial production. (S)-2-(4-((3-((1-methylpyrrolidin-2-yl)methyl)-1H-indol-5-yl)oxy)butyl)isoindoline-1,3-dione vendor & factory After a four-year battle over a cancer drug patent, Novartis has been ordered by a California judge to pay a Daiichi Sankyo subsidiary $177.8 million.,The Company most recently announced plans to establish a dedicated laboratory space with Biosafety Level-3 (BSL-3) containment to handle testing of SARS-CoV-2 (the viral strain causing COVID-19) and other similar pathogens that cause human disease.
